Aurinia Pharmaceuticals (NASDAQ:AUPH) initiates a Phase 2 clinical trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). It will compare VOS 0.2% against Allergan's (NYSE:AGN) RESTASIS (cyclosporine ophthalmic emulsion 0.05%) over a four-week treatment period in 90 patients with mild-to-moderate DES.
The primary endpoint will be tolerability. Secondary endpoints include efficacy measures. The trial should be completed by year-end.
Shares are up 2% after hours.
Now read: Will Mullets Bail Out Allergan? »
Subscribe for full text news in your inbox